JP2017503850A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503850A5
JP2017503850A5 JP2016554306A JP2016554306A JP2017503850A5 JP 2017503850 A5 JP2017503850 A5 JP 2017503850A5 JP 2016554306 A JP2016554306 A JP 2016554306A JP 2016554306 A JP2016554306 A JP 2016554306A JP 2017503850 A5 JP2017503850 A5 JP 2017503850A5
Authority
JP
Japan
Prior art keywords
compound
salt
alkyl
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503850A (ja
JP6670751B2 (ja
Filing date
Publication date
Priority claimed from US14/208,657 external-priority patent/US9265765B2/en
Priority claimed from PCT/US2014/048241 external-priority patent/WO2015073072A1/en
Priority claimed from US14/341,392 external-priority patent/US9376437B2/en
Application filed filed Critical
Priority claimed from PCT/US2014/055373 external-priority patent/WO2015073109A1/en
Publication of JP2017503850A publication Critical patent/JP2017503850A/ja
Publication of JP2017503850A5 publication Critical patent/JP2017503850A5/ja
Application granted granted Critical
Publication of JP6670751B2 publication Critical patent/JP6670751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554306A 2013-11-15 2014-09-12 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法 Active JP6670751B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361904718P 2013-11-15 2013-11-15
US61/904,718 2013-11-15
US14/208,657 US9265765B2 (en) 2013-03-13 2014-03-13 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
US14/208,657 2014-03-13
USPCT/US2014/048241 2014-07-25
PCT/US2014/048241 WO2015073072A1 (en) 2013-11-15 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US14/341,392 2014-07-25
US14/341,392 US9376437B2 (en) 2013-03-13 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PCT/US2014/055373 WO2015073109A1 (en) 2013-11-15 2014-09-12 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233099A Division JP2020097577A (ja) 2013-11-15 2019-12-24 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017503850A JP2017503850A (ja) 2017-02-02
JP2017503850A5 true JP2017503850A5 (enExample) 2017-10-12
JP6670751B2 JP6670751B2 (ja) 2020-03-25

Family

ID=53057842

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016554306A Active JP6670751B2 (ja) 2013-11-15 2014-09-12 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法
JP2019233099A Pending JP2020097577A (ja) 2013-11-15 2019-12-24 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法
JP2022076459A Pending JP2022105170A (ja) 2013-11-15 2022-05-06 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法
JP2024027134A Pending JP2024059840A (ja) 2013-11-15 2024-02-27 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019233099A Pending JP2020097577A (ja) 2013-11-15 2019-12-24 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その塩及びその使用方法
JP2022076459A Pending JP2022105170A (ja) 2013-11-15 2022-05-06 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法
JP2024027134A Pending JP2024059840A (ja) 2013-11-15 2024-02-27 7-ベンジル-4-(2-メチルベンジル)-2,4,6,7,8,9-ヘキサヒドロイミダゾ[1,2-a]ピリド[3,4-e]ピリミジン-5(1h)-オン、その塩及びその使用方法

Country Status (25)

Country Link
EP (3) EP3939594A1 (enExample)
JP (4) JP6670751B2 (enExample)
KR (5) KR102453679B1 (enExample)
CN (2) CN106163524B (enExample)
AU (4) AU2014349150B2 (enExample)
BR (1) BR112016011072B1 (enExample)
CA (2) CA2930535C (enExample)
CY (2) CY1121628T1 (enExample)
DK (2) DK3546461T3 (enExample)
EA (1) EA033744B1 (enExample)
ES (2) ES2724331T3 (enExample)
HR (2) HRP20211653T8 (enExample)
HU (2) HUE056389T2 (enExample)
IL (6) IL311202A (enExample)
LT (2) LT3546461T (enExample)
ME (1) ME03387B (enExample)
MX (3) MX390132B (enExample)
PL (2) PL3546461T3 (enExample)
PT (2) PT3546461T (enExample)
RS (2) RS58745B1 (enExample)
SG (1) SG10201809189UA (enExample)
SI (2) SI3546461T1 (enExample)
SM (2) SMT201900291T1 (enExample)
TR (1) TR201906711T4 (enExample)
WO (1) WO2015073109A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2724331T3 (es) 2013-11-15 2019-09-10 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso
MD3805222T2 (ro) * 2015-01-30 2025-04-30 Oncoceutics Inc Derivați de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sărurile acestora și utilizarea acestora în terapie
DK3408298T3 (en) * 2016-01-29 2025-03-03 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
MA45280B1 (fr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
EP3849559A4 (en) * 2018-09-12 2022-06-01 Denovo Biopharma LLC COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF
KR102536315B1 (ko) 2020-09-11 2023-05-25 아주대학교산학협력단 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
EP4684834A1 (de) 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
CA2478338A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US20080221135A1 (en) * 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
NZ593343A (en) * 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
US9724337B2 (en) * 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
JP5863058B2 (ja) * 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1H−イミダゾ[4,5−c]キノリン
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
AU2012240246A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
SMT202000272T1 (it) 2011-04-29 2020-07-08 Penn State Res Found Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
KR20220123335A (ko) * 2013-03-13 2022-09-06 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
ES2724331T3 (es) 2013-11-15 2019-09-10 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso
ES2999685T3 (en) * 2014-03-31 2025-02-26 Scripps Research Inst Pharmacophore for trail induction

Similar Documents

Publication Publication Date Title
EP4328229A3 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
JP2015508103A5 (enExample)
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
JP2014221779A5 (enExample)
EP4227304A3 (en) Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons
JP2017514910A5 (enExample)
JP2016532715A5 (enExample)
JP2017508782A5 (enExample)
JP2015078230A5 (enExample)
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2016528301A5 (enExample)
JP2017501237A5 (enExample)
JP2016514159A5 (enExample)
JP2011105738A5 (enExample)
JP2016518328A5 (enExample)
JP2016507581A5 (enExample)
JP2018521020A5 (enExample)
JP2015508092A5 (enExample)
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
JP2017517565A5 (enExample)
JP2018501215A5 (enExample)
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados